RAD51 Inhibitor B02 NEW
| Price | $41 | $67 | $98 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: RAD51 Inhibitor B02 | CAS No.: 1290541-46-6 |
| Purity: 99.89% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | RAD51 Inhibitor B02 |
| Description | RAD51 Inhibitor B02 (B02) (B02) is an inhibitor of human RAD51 with an IC50 of 27.4 μM. |
| In vitro | RAD51 Inhibitor B02 selectively inhibits human RAD51 (IC50 = 27.4 μM) without affecting its E. coli homologue RecA (IC50 > 250 μM). Combining B02 with cisplatin exhibits a potent cytotoxic effect on human breast cancer cells [MDA-MB-231].' |
| In vivo | B02 substantially improves the therapeutic efficacy of cisplatin against tumor cells in vivo, demonstrating tolerability in mice at dosages up to 50 mg/kg without significant body weight reduction. Mice treated solely with B02 exhibited no tumor growth inhibition; however, those administered 4 mg/kg of cisplatin experienced a 33% reduction in tumor growth. Crucially, a combination treatment involving 50 mg/kg B02 and 4 mg/kg cisplatin resulted in a 66% decrease in tumor size[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 33.9 mg/mL (100 mM) |
| Keywords | RAD51 Inhibitor B02 | B 02 | Apoptosis | RAD-51 Inhibitor B02 | RAD51 | Inhibitor | B-02 | inhibit |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Guanidine hydrochloride | Metronidazole | Sorafenib | Tributyrin | Thymidine |
| Related Compound Libraries | Apoptosis Compound Library | DNA Damage & Repair Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1970.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $0.00/5Kg |
VIP1Y
|
SHANGHAI GEM CHEMICAL INDUSTRY CO.,LTD.
|
2024-12-23 | |
| $0.00/200kg |
VIP2Y
|
Nanjing Huazhou New Material Co., Ltd.
|
2024-02-26 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY